[Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].

Objective: To explore the efficacy and side effects of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

Methods: The efficacy and side effects of icotinib hydrochloride in treatment of 59 cases with stage IV NSCIC and followed-up from March 2009 to January 2012 were retrospectively analyzed.

Results: Twenty seven patients (45.